PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för ixazomib citrate. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

14 hits

Bibliografisk träff 2015-11-13

Proteasome Inhibition Suppresses Dengue Virus Egress in Antibody Dependent Infection.

Choy MM, Zhang SL, Costa VV, Tan HC, Horrevorts S, Ooi EE.

PLoS Negl Trop Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pntd.0004058

Bibliografisk träff 2015-08-14

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib.

Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A.

Blood Cancer J · clinical trial, phase ii; research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/bcj.2015.60

Bibliografisk träff 2015-04-29

Proteasome inhibitors.

Teicher BA, Tomaszewski JE.

Biochem Pharmacol · journal article · DOI 10.1016/j.bcp.2015.04.008

Bibliografisk träff 2015-03-10

TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.

Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, Tokuhira M, Ri M, Hashimoto Y, Iida S, Kizaki M.

Cancer Sci · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/cas.12616

Bibliografisk träff 2015-01-01

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

Richardson PG, Moreau P, Laubach JP, Gupta N, Hui AM, Anderson KC, San Miguel JF, Kumar S.

Future Oncol · review; journal article · DOI 10.2217/fon.15.9

Bibliografisk träff 2014-10-17

Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.

Assouline SE, Chang J, Cheson BD, Rifkin R, Hamburg S, Reyes R, Hui AM, Yu J, Gupta N, Di Bacco A, Shou Y, Martin P.

Blood Cancer J · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1038/bcj.2014.71

Bibliografisk träff 2014-09-29

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.

Offidani M, Corvatta L, Caraffa P, Gentili S, Maracci L, Leoni P.

Onco Targets Ther · review-article; review; journal article · DOI 10.2147/ott.s49187

Bibliografisk träff 2014-06-11

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.

Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S.

Blood · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1182/blood-2014-01-548826

Bibliografisk träff 2014-06-05

Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.

Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di Bacco A, Yu J, Shou Y, Niesvizky R.

Blood · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1182/blood-2014-01-548941

Bibliografisk träff 2014-04-15

Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).

Niewerth D, Jansen G, Riethoff LF, van Meerloo J, Kale AJ, Moore BS, Assaraf YG, Anderl JL, Zweegman S, Kaspers GJ, Cloos J.

Mol Pharmacol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/mol.114.092114

Bibliografisk träff 2014-01-31

Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.

Garcia-Gomez A, Quwaider D, Canavese M, Ocio EM, Tian Z, Blanco JF, Berger AJ, Ortiz-de-Solorzano C, Hernández-Iglesias T, Martens AC, Groen RW, Mateo-Urdiales J, Fraile S, Galarraga M, Chauhan D, San Miguel JF, Raje N, Garayoa M.

Clin Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/1078-0432.ccr-13-1657

Bibliografisk träff 2013-11-29

(18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib.

Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F, Tricot G, Acevedo MR, Ponto LL, Walsh SA, Tygrett LT, Berger AJ, Waldschmidt T, Morse HC, Sunderland JJ, Janz S.

Blood Cancer J · research-article; journal article · DOI 10.1038/bcj.2013.61

Bibliografisk träff 2013-09-01

Contemporary drug therapies for multiple myeloma.

de la Puente P, Azab AK.

Drugs Today (Barc) · review; journal article · DOI 10.1358/dot.2013.49.9.2020941

Bibliografisk träff 2013-07-09

Syntheses of C-13 and C-14-labeled versions of the investigational proteasome inhibitor MLN9708.

Plesescu M, Elliott EL, Li Y, Prakash SR.

J Labelled Comp Radiopharm · journal article · DOI 10.1002/jlcr.3079